These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33277054)

  • 1. GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma.
    Xiong L; Li X; Chen D; Li S; Luo L
    Lung Cancer; 2021 Jan; 151():104-105. PubMed ID: 33277054
    [No Abstract]   [Full Text] [Related]  

  • 2. A Rare Fusion of CLIP1 and ALK in a Case of Non-Small-Cell Lung Cancer With Neuroendocrine Features.
    Pinsolle J; Mondet J; Duruisseaux M; d'Alnoncourt S; Magnat N; de Fraipont F; Moro-Sibilot D; Toffart AC; Brambilla E; McLeer-Florin A
    Clin Lung Cancer; 2019 Sep; 20(5):e535-e540. PubMed ID: 31171381
    [No Abstract]   [Full Text] [Related]  

  • 3. Case Report: Temporal Heterogeneity of ALK Activating Mutations in Sequential ALK TKI-Treated Non-Small-Cell Lung Cancer Revealed Using NGS-Based Liquid Biopsy.
    Ding M; Deng L; Yu R; Lu D; Bai Y; Wu X; Shao YW; Yang Y
    Clin Lung Cancer; 2019 May; 20(3):e229-e232. PubMed ID: 30948231
    [No Abstract]   [Full Text] [Related]  

  • 4. SPECC1L-ALK: A novel gene fusion response to ALK inhibitors in non-small cell lung cancer.
    Ma L; Zhang Q; Dong Y; Li H; Wang J
    Lung Cancer; 2020 May; 143():97-100. PubMed ID: 32216970
    [No Abstract]   [Full Text] [Related]  

  • 5. A Novel Nonreciprocal/Reciprocal ALK Translocation Cause ALK+ in NSCLC.
    Chen X; Xu BO; Fu F; Cai K; Yu Z
    Lung Cancer; 2021 Aug; 158():162-163. PubMed ID: 34045098
    [No Abstract]   [Full Text] [Related]  

  • 6. Front-line treatment of ceritinib improves efficacy over crizotinib for Asian patients with anaplastic lymphoma kinase fusion NSCLC: The role of systemic progression control.
    Huang SH; Huang AC; Wang CC; Chang WC; Liu CY; Pavlidis S; Ko HW; Chung FT; Hsu PC; Guo YK; Kuo CS; Yang CT
    Thorac Cancer; 2019 Dec; 10(12):2274-2281. PubMed ID: 31613427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance Mechanisms to Targeted Therapies in
    McCoach CE; Le AT; Gowan K; Jones K; Schubert L; Doak A; Estrada-Bernal A; Davies KD; Merrick DT; Bunn PA; Purcell WT; Dziadziuszko R; Varella-Garcia M; Aisner DL; Camidge DR; Doebele RC
    Clin Cancer Res; 2018 Jul; 24(14):3334-3347. PubMed ID: 29636358
    [No Abstract]   [Full Text] [Related]  

  • 8. 5'/ 3' imbalance strategy to detect ALK fusion genes in circulating tumor RNA from patients with non-small cell lung cancer.
    Tong Y; Zhao Z; Liu B; Bao A; Zheng H; Gu J; McGrath M; Xia Y; Tan B; Song C; Li Y
    J Exp Clin Cancer Res; 2018 Mar; 37(1):68. PubMed ID: 29587818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
    Zhang J; Zou C; Zhou C; Luo Y; He Q; Sun Y; Zhou J; Ke Z
    J Thorac Oncol; 2020 Jun; 15(6):1073-1077. PubMed ID: 32217130
    [No Abstract]   [Full Text] [Related]  

  • 10. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction of CTC-ALK gene fusion detection system based on the multi-site magnetic separation in lung cancer and its clinical verification.
    Ma AP; Guo WX; Gao DH; Ke MY; Luo Q; Liu Q
    Neoplasma; 2020 Nov; 67(6):1233-1243. PubMed ID: 32853016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of patients with surgically resected lung cancer having tumours harboring anaplastic lymphoma kinase fusion protein.
    Chen B; Jiang Z; Li C; Lu H
    J Pak Med Assoc; 2020 Apr; 70(4):747-750. PubMed ID: 32296229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance.
    Vollbrecht C; Lenze D; Hummel M; Lehmann A; Moebs M; Frost N; Jurmeister P; Schweizer L; Kellner U; Dietel M; von Laffert M
    BMC Cancer; 2018 Nov; 18(1):1158. PubMed ID: 30466405
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of known and novel ALK fusion transcripts in lung cancer patients using next-generation sequencing approaches.
    Vendrell JA; Taviaux S; Béganton B; Godreuil S; Audran P; Grand D; Clermont E; Serre I; Szablewski V; Coopman P; Mazières J; Costes V; Pujol JL; Brousset P; Rouquette I; Solassol J
    Sci Rep; 2017 Oct; 7(1):12510. PubMed ID: 28970558
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARD3-ALK: A novel ALK fusion gene identified in a patient with lung adenocarcinoma.
    Yang L; Zhao W; Zhu H; Li X; Zhao G
    Lung Cancer; 2021 Apr; 154():219-220. PubMed ID: 33676770
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.
    Peters S; Zimmermann S
    Curr Treat Options Oncol; 2018 May; 19(7):37. PubMed ID: 29808239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of
    He Y; Sun LY; Gong R; Liu Q; Long YK; Liu F; Wang F
    Biomark Med; 2019 Aug; 13(12):1035-1044. PubMed ID: 31432686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Response to crizotinib in advanced ALK-rearranged non-small cell lung cancers with different ALK-fusion variants.
    Li Y; Zhang T; Zhang J; Li W; Yuan P; Xing P; Zhang Z; Chuai S; Li J; Ying J
    Lung Cancer; 2018 Apr; 118():128-133. PubMed ID: 29571990
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of ALK detection by FISH, IHC and NGS to predict benefit from crizotinib in advanced non-small-cell lung cancer.
    Lin C; Shi X; Yang S; Zhao J; He Q; Jin Y; Yu X
    Lung Cancer; 2019 May; 131():62-68. PubMed ID: 31027700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ALK fusion variants detection by targeted RNA-next generation sequencing and clinical responses to crizotinib in ALK-positive non-small cell lung cancer.
    McLeer-Florin A; Duruisseaux M; Pinsolle J; Dubourd S; Mondet J; Phillips Houlbracq M; Magnat N; Fauré J; Chatagnon A; de Fraipont F; Giaj Levra M; Toffart AC; Ferretti G; Hainaut P; Brambilla E; Moro-Sibilot D; Lantuejoul S
    Lung Cancer; 2018 Feb; 116():15-24. PubMed ID: 29413046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.